真实世界环境中启动阿巴洛肽、特立帕肽或地舒单抗治疗的患者特征:美国理赔与电子病历关联数据库分析
基于美国约2亿患者理赔与电子病历数据,描述2017年5月1日至2018年9月24日启动阿巴洛肽、特立帕肽或地舒单抗治疗的患者特征。与地舒单抗相比,启动阿巴洛肽和特立帕肽的患者在性别、年龄、病理性骨折、共病指数及既往双膦酸盐使用方面存在差异。
要点
- 启动阿巴洛肽和特立帕肽的患者较地舒单抗更年轻,女性比例更高。
- 阿巴洛肽和特立帕肽组既往病理性/脆性骨折比例约为地舒单抗组的近两倍。
- 阿巴洛肽和特立帕肽组共病指数≥2的比例低于地舒单抗组。
核心结论
- 与启动地舒单抗的患者相比,启动阿巴洛肽和特立帕肽的患者在性别、年龄、病理性骨折、共病指数及既往双膦酸盐使用方面存在差异。
研究设计与样本
- 利用OM1数据云(包含约2亿美国患者的医疗和药房理赔数据)识别2017年5月1日至2018年9月24日期间启动阿巴洛肽、特立帕肽或地舒单抗且既往12个月未使用同一药物的≥18岁患者。
主要发现
- 研究期间启动阿巴洛肽2666例、特立帕肽9210例、地舒单抗116718例。
- 平均年龄(标准差):阿巴洛肽组69.2(10.6)岁,特立帕肽组68.6(11.3)岁,地舒单抗组72.1(10.2)岁(P < 0.001;阿巴洛肽 vs 地舒单抗)。
- 女性比例:阿巴洛肽组95.2%,特立帕肽组86.9%,地舒单抗组91.3%(P < 0.001;阿巴洛肽 vs 特立帕肽或地舒单抗)。
- 既往病理性/脆性骨折比例:阿巴洛肽组19.1%,特立帕肽组18.8%,地舒单抗组9.6%(P < 0.001;阿巴洛肽 vs 地舒单抗)。
- Charlson共病指数≥2的比例:阿巴洛肽组36.3%,特立帕肽组39.7%,地舒单抗组48.4%(P < 0.001;阿巴洛肽 vs 地舒单抗)。
关键数值与推荐
- 启动前有既往骨质疏松治疗的比例:阿巴洛肽组44.3%,特立帕肽组33.8%,地舒单抗组33.9%。
- 启动前有双膦酸盐使用比例:阿巴洛肽组19.2%,特立帕肽组19.6%,地舒单抗组16.6%(P < 0.001;阿巴洛肽 vs 地舒单抗)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We characterized patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) in a real-world clinical setting from a large medical and pharmacy claims database. Differences were noted in sex, age, pathologic fractures, comorbidity index, and prior bisphosphonate use for patients initiating ABL and TPTD compared with those receiving DMAB. INTRODUCTION: To characterize patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) treatment in a real-world clinical setting. METHODS: Patients aged ≥ 18 years initiating ABL, TPTD, or DMAB between May 1, 2017, and September 24, 2018 (without receiving the same drug in the previous 12 months), were identified using the OM1 Data Cloud, which contains medical and pharmacy claims from approximately 200 million US patients. The index date was the date of initial prescription or dispensing for ABL, TPTD, or DMAB during the study period. RESULTS: During the study period, 2666 patients initiated ABL, 9210 TPTD, and 116,718 DMAB. Mean age (standard deviation) was 69.2 (10.6) years for the ABL cohort, 68.6 (11.3) for TPTD, and 72.1 (10.2) for DMAB (P < 0.001; ABL vs DMAB). Proportionally more patients initiating ABL were female (95.2% ABL, 86.9% TPTD, and 91.3% DMAB, P < 0.001 ABL vs TPTD or DMAB). Nearly twice as many patients initiating ABL (19.1%) and TPTD (18.8%) had a previous pathologic/fragility fracture vs DMAB (9.6%; P < 0.001 ABL vs DMAB). Fewer patients initiating ABL (36.3%) or TPTD (39.7%) had Charlson comorbidity index of ≥ 2 vs DMAB (48.4%; P < 0.001 ABL vs DMAB). Before initiating ABL, TPTD, or DMAB, 44.3%, 33.8%, and 33.9% of patients had prior osteoporosis treatment, respectively. Bisphosphonate use was more common before initiating ABL (19.2%) or TPTD (19.6%), than before initiating DMAB (16.6%; P < 0.001 ABL vs DMAB). CONCLUSIONS: Patients initiating ABL and TPTD differed in sex, age, pathologic fractures, comorbidity index, and prior bisphosphonate use compared with those initiating DMAB.
引用
- Imel EA, Starzyk K, Gliklich R, et al. Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis. Osteoporos Int. 2020. PMID: 32696118. doi:10.1007/s00198-020-05388-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。